Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Total Assets of $74.31 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -34.4% in Total Assets from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $67.86 million | Q3 2011: $63.27 million | Q1 2012: $55.35 million | Q2 2012: $48.60 million | Q3 2012: $44.48 million | Q1 2013: $58.20 million | Q2 2013: $50.99 million | Q3 2013: $88.02 million | Q1 2014: $151.66 million | Q2 2014: $142.15 million | Q3 2014: $134.53 million | Q1 2015: $117.86 million | Q2 2015: $201.70 million | Q3 2015: $230.77 million | Q1 2016: $211.29 million | Q2 2016: $203.99 million | Q3 2016: $194.55 million | Q1 2017: $153.31 million | Q2 2017: $158.85 million | Q3 2017: $203.68 million | Q1 2018: $173.66 million | Q2 2018: $148.92 million | Q3 2018: $140.70 million | Q1 2019: $191.17 million | Q2 2019: $165.07 million | Q3 2019: $151.53 million | Q1 2020: $338.92 million | Q2 2020: $443.19 million | Q3 2020: $437.81 million | Q1 2021: $654.86 million | Q2 2021: $591.84 million | Q3 2021: $535.76 million | Q1 2022: $445.51 million | Q2 2022: $459.40 million | Q3 2022: $391.97 million | Q1 2023: $266.58 million | Q2 2023: $233.04 million | Q3 2023: $193.10 million | Q1 2024: $129.11 million | Q2 2024: $133.80 million | Q3 2024: $107.06 million | Q1 2025: $87.27 million | Q2 2025: $68.24 million | Q3 2025: $69.39 million.
- Over the full 16 years of available data (2010 to 2025), INOVIO PHARMACEUTICALS, INC.'s Total Assets has grown by 32.5%.
- Historical annual values: Fiscal year 2025: $74.31 million | Fiscal year 2024: $113.20 million | Fiscal year 2023: $170.95 million | Fiscal year 2022: $348.53 million | Fiscal year 2021: $495.94 million | Fiscal year 2020: $539.77 million | Fiscal year 2019: $143.95 million | Fiscal year 2018: $131.11 million | Fiscal year 2017: $187.24 million | Fiscal year 2016: $173.71 million | Fiscal year 2015: $213.84 million | Fiscal year 2014: $131.79 million | Fiscal year 2013: $88.29 million | Fiscal year 2012: $45.14 million | Fiscal year 2011: $61.11 million | Fiscal year 2010: $56.07 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: